Guardant Health Inc GH:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/14/24 EDT
24.73quote price arrow up+0.73 (+3.04%)
Volume
3,912,177
52 week range
15.81 - 41.06
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close24.73
  • 52 Week High41.06
  • 52 Week High Date08/30/23
  • 52 Week Low15.81
  • 52 Week Low Date04/19/24

Key Stats

  • Market Cap3.014B
  • Shares Out121.89M
  • 10 Day Average Volume2.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.11
  • YTD % Change-8.58

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close24.73
  • 52 Week High41.06
  • 52 Week High Date08/30/23
  • 52 Week Low15.81
  • 52 Week Low Date04/19/24
  • Market Cap3.014B
  • Shares Out121.89M
  • 10 Day Average Volume2.42M
  • Dividend-
  • Dividend Yield-
  • Beta1.11
  • YTD % Change-8.58

RATIOS/PROFITABILITY

  • EPS (TTM)-3.92
  • P/E (TTM)-6.31
  • Fwd P/E (NTM)-8.06
  • EBITDA (TTM)-487.105M
  • ROE (TTM)-3,883.89%
  • Revenue (TTM)603.725M
  • Gross Margin (TTM)60.37%
  • Net Margin (TTM)-76.34%
  • Debt To Equity (MRQ)1,670.37%

EVENTS

  • Earnings Date08/01/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Guardant Health Inc

 

Profile

MORE
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select...
Helmy Eltoukhy Ph.D.
Chairman of the Board, Co-Chief Executive Officer
Michael Bell
Chief Financial Officer
Kumud Kalia
Chief Information Officer
Address
3100 Hanover Street
Palo Alto, CA
94304
United States

Top Peers

SYMBOLLASTCHG%CHG
TXG
10X Genomics Inc
26.56-0.41-1.52%
FOLD
Amicus Therapeutics Inc
9.33+0.29+3.21%
ACAD
ACADIA Pharmaceuticals Inc
14.86-0.32-2.11%
MYGN
Myriad Genetics Inc
25.36+0.43+1.72%
NVCR
Novocure Ltd
20.32+2.34+13.01%